Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485046 | 0.84 | L3MBTL1 (0.53) | L3MBTL1PTGDR2KDM4EPOLBALOX5 | |
| SCHEMBL2481905 | 0.77 | L3MBTL1 (0.50) | L3MBTL1PTGDR2KDM4EPOLBALDH1A1 | |
| SCHEMBL12030461 | 0.75 | L3MBTL1 (0.51) | L3MBTL1PTGDR2KDM4EPOLBALOX5 | |
| SCHEMBL27897368 | 0.74 | SMN1; SMN2 (0.54) | L3MBTL1PTGDR2KDM4EPOLBALDH1A1 | |
| SCHEMBL2483872 | 0.73 | L3MBTL1 (0.55) | L3MBTL1PTGDR2KDM4EPOLBALOX5 | |
| SCHEMBL4574123 | 0.72 | L3MBTL1 (0.51) | L3MBTL1PTGDR2KDM4EPOLBALOX5 | |
| SCHEMBL12030444 | 0.72 | L3MBTL1 (0.54) | L3MBTL1PTGDR2KDM4EPOLBALDH1A1 | |
| SCHEMBL12049696 | 0.70 | L3MBTL1 (0.58) | L3MBTL1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL6602729 | 0.69 | L3MBTL1 (0.74) | L3MBTL1PTGDR2KDM4EPOLBALDH1A1 | |
| SCHEMBL2483841 | 0.69 | L3MBTL1 (0.59) | L3MBTL1KDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376502-B1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2376502-B1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| CN-102388054-B | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2015-03-04 | — | — | CN | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| CN-102388054-A | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2012-03-21 | — | — | CN | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| EP-2376502-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071853-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | L3MBTL1 4230/4885PTGDR2 2563/4885KDM4E 2933/4885 |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | L3MBTL1 4230/4885PTGDR2 2563/4885KDM4E 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.